Paper22945653
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays.
Gujral TS and 6 others. Oncogene, 2013. Cited by 66 papers, by iCite.
Cite this record
ConductScience Library. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Papers, record 22945653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22945653
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Protein Array Analysis | Major topic |
| Signal Transduction | Major topic |
| Cluster Analysis | |
| Female | |
| Humans | |
| Proteomics | |
| Proto-Oncogene Proteins | |
| Proto-Oncogene Proteins c-met | |
| Receptor Protein-Tyrosine Kinases | |
| Axl Receptor Tyrosine Kinase |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21 CA126720 | NCI NIH HHS | United States | R21CA126720 | PubMed and NIH | NIH RePORTER |
| R33 CA128726 | NCI NIH HHS | United States | R33CA128726 | PubMed and NIH | NIH RePORTER |
| RC1 HG005354 | NHGRI NIH HHS | United States | RC1HG005354 | PubMed and NIH | NIH RePORTER |
| 5RC1-HG005354 | NHGRI NIH HHS | United States | RC1HG005354 | PubMed and NIH | NIH RePORTER |
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3798106 | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | Science | 1987 | https://conductscience.org/library/papers/3798106 | PubMed |
| 2 | 21296872 | Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling. | Mol Cell Proteomics | 2011 | https://conductscience.org/library/papers/21296872 | PubMed |
| 3 | 16857357 | Bead-based microfluidic immunoassays: the next generation. | Biosens Bioelectron | 2007 | https://conductscience.org/library/papers/16857357 | PubMed |
| 4 | 18957207 | Cytokine-induced signaling networks prioritize dynamic range over signal strength. | Cell | 2008 | https://conductscience.org/library/papers/18957207 | PubMed |
| 5 | 20460509 | Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. | Cancer Res | 2010 | https://conductscience.org/library/papers/20460509 | PubMed |
| 6 | 12666998 | Detection of multiple cytokines by protein arrays from cell lysate and tissue lysate. | Clin Chem Lab Med | 2003 | https://conductscience.org/library/papers/12666998 | PubMed |
| 7 | 21057535 | Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. | Oncogene | 2011 | https://conductscience.org/library/papers/21057535 | PubMed |
| 8 | 16775003 | Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor. | Mol Biol Cell | 2006 | https://conductscience.org/library/papers/16775003 | PubMed |
| 9 | 16737840 | Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. | Cytokine Growth Factor Rev | 2006 | https://conductscience.org/library/papers/16737840 | PubMed |
| 10 | 17967179 | A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. | Mol Cancer | 2007 | https://conductscience.org/library/papers/17967179 | PubMed |
| 11 | 21655918 | Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. | Invest New Drugs | 2012 | https://conductscience.org/library/papers/21655918 | PubMed |
| 12 | 17325667 | A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. | Oncogene | 2007 | https://conductscience.org/library/papers/17325667 | PubMed |
| 13 | 21814748 | Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. | Breast Cancer Res Treat | 2011 | https://conductscience.org/library/papers/21814748 | PubMed |
| 14 | 16407846 | A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. | Oncogene | 2006 | https://conductscience.org/library/papers/16407846 | PubMed |
| 15 | 16322262 | Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. | Cancer Res | 2005 | https://conductscience.org/library/papers/16322262 | PubMed |
| 16 | 20015007 | Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. | Anticancer Agents Med Chem | 2010 | https://conductscience.org/library/papers/20015007 | PubMed |
| 17 | 8100853 | Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. | J Pathol | 1993 | https://conductscience.org/library/papers/8100853 | PubMed |
| 18 | 20080645 | Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20080645 | PubMed |
| 19 | 20720570 | Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. | Nat Rev Cancer | 2010 | https://conductscience.org/library/papers/20720570 | PubMed |
| 20 | 15455388 | C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. | Int J Cancer | 2005 | https://conductscience.org/library/papers/15455388 | PubMed |
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41665993 | A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41665993 | PubMed |
| 40567015 | Text Mining Strategy Identifies Gene Networks Under Control of miR-21 in Breast Cancer Development. | Cancer Med | 2025 | https://conductscience.org/library/papers/40567015 | PubMed |
| 39924521 | AXL signaling in cancer: from molecular insights to targeted therapies. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39924521 | PubMed |
| 39769140 | The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769140 | PubMed |
| 38724493 | Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis. | Nat Commun | 2024 | https://conductscience.org/library/papers/38724493 | PubMed |
| 38507737 | A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/38507737 | PubMed |
| 36341335 | Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors. | Front Immunol | 2022 | https://conductscience.org/library/papers/36341335 | PubMed |
| 35946957 | βIII-tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c-Met positive non-small cell lung cancer cells. | Cancer Med | 2023 | https://conductscience.org/library/papers/35946957 | PubMed |
| 35705369 | Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. | Gut | 2023 | https://conductscience.org/library/papers/35705369 | PubMed |
| 35406510 | Proteomic and Transcriptomic Profiling Reveals Mitochondrial Oxidative Phosphorylation as Therapeutic Vulnerability in Androgen Receptor Pathway Active Prostate Tumors. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35406510 | PubMed |
| 34939009 | Mesangioproliferative Kidney Diseases and Platelet-Derived Growth Factor-Mediated AXL Phosphorylation. | Kidney Med | 2021 | https://conductscience.org/library/papers/34939009 | PubMed |
| 34593636 | Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34593636 | PubMed |
| 32645560 | Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma. | Neoplasia | 2020 | https://conductscience.org/library/papers/32645560 | PubMed |
| 32148495 | AXL as a Target in Breast Cancer Therapy. | J Oncol | 2020 | https://conductscience.org/library/papers/32148495 | PubMed |
| 32051483 | (-)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells. | Sci Rep | 2020 | https://conductscience.org/library/papers/32051483 | PubMed |
| 31196969 | Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability. | Mol Cell Proteomics | 2019 | https://conductscience.org/library/papers/31196969 | PubMed |
| 30279968 | Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. | Oncotarget | 2018 | https://conductscience.org/library/papers/30279968 | PubMed |
| 29907679 | The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. | EMBO Rep | 2018 | https://conductscience.org/library/papers/29907679 | PubMed |
| 29507545 | Current applications of antibody microarrays. | Clin Proteomics | 2018 | https://conductscience.org/library/papers/29507545 | PubMed |
| 28638489 | Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. | Theranostics | 2017 | https://conductscience.org/library/papers/28638489 | PubMed |
Genes38
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22945653
GET https://conductscience.org/api/papers/v1/22945653/references?page=2